Vertex Pharmaceuticals is ranked among the best biotech stocks to buy, with 13 billionaires backing the company. Despite ...

Ed Kaye, former CEO of Sarepta Therapeutics, is stepping down from his current role as chief executive of a Boston-area ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

In a report released today, Gena Wang from Barclays maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report), with a price ...

We recently published a list of 13 High Growth Large Cap Stocks To Invest In. In this article, we are going to take a look at ...

Shares of Vertex Pharmaceuticals have received an average “Moderate Buy” rating from 26 brokerages. Analysts are divided, ...

This was the stock's fourth consecutive day of gains.

In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the ...